Type 1 Diabetes

The prevalence of diabetes is increasing faster in some low-income countries than elsewhere in the world, generating concerns about health care infrastructure and access to treatment for people in those regions.

Sodium-glucose cotransporter 2, or SGLT2, inhibitors may be more cardioprotective for older adults, whereas glucagon-like peptide-1 receptor agonists may confer greater HbA1c reductions in that population, according to a systematic review and meta-analysis.

The use of a continuous glucose monitor during pregnancy may be more cost-effective than self-monitoring blood glucose for women with type 1 diabetes, according to a brief report published in Diabetes Technology & Therapeutics.

Adults with type 1 diabetes who partake in weight cycling and repeatedly lose and regain body weight are more likely to develop diabetic kidney disease, researchers reported in The Journal of Clinical Endocrinology & Metabolism.

A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, including measuring body fat to diagnose obesity instead of BMI alone.

Pregnant women with type 2 diabetes have a greater risk for perinatal mortality vs. pregnant women with type 1 diabetes, gestational diabetes and no diabetes, researchers reported in the American Journal of Obstetrics and Gynecology.

For the second time since 2019, the oral SGLT1 and SGLT2 dual inhibitor sotagliflozin has been denied FDA approval for adults with type 1 diabetes, with elevated risk for diabetic ketoacidosis being a primary concern.

New guidance on GLP-1 receptor agonist use, how to tackle medication shortages and expanded continuous glucose monitoring use for type 2 diabetes are among the updates in the American Diabetes Association’s 2025 Standards of Care.

Use of the dual SGLT1/SGLT2 inhibitor sotagliflozin was associated with similar HbA1c reduction for patients with type 1 diabetes using insulin whether or not they also had chronic kidney disease, according to study data.

Children who attend day care are 32% less likely to develop type 1 diabetes compared with children who do not go to day care, according to a systematic review and meta-analysis published in JAMA Pediatrics.